Key result
COVID-19 pandemic linked to ~50% higher diabetes mortality in Kazakhstan.
Why the study?
Patients with diabetes are among the most vulnerable during the COVID-19 pandemic, necessitating research on morbidity, mortality, and survival dynamics before and during the pandemic in Kazakhstan.
Observational (n=1,903,243)
Absolute Event Rate: 34.1% vs 22.3%
During the COVID-19 pandemic period in Kazakhstan, increases in diabetes-related morbidity and mortality were predominantly driven by type 2 diabetes in women.
Diabetes mortality rose during the pandemic in Kazakhstan; leaves open generalizability and mechanisms for prospective confirmation.
Background: During the COVID-19 pandemic, patients with diabetes are among the most vulnerable. Our purpose is to research the dynamics of morbidity, mortality, and survival of patients with diabetes in Kazakhstan before and during the current pandemic. Methods: The indicators were calculated taking into account gender and nosological forms (E10-E14, according to ICD-10).The survival analysis was performed by the method of constructing survival tables and the Kaplan-Meier method. Based on methods, the official reporting data of 1,903,243 cases of diabetes and 20,605 deaths from diabetes were analyzed for the period 2018-2021. Results: = 0.001). Conclusion: To a greater extent, the increase in diseases and terminal outcomes occurred due to non-insulin-dependent type (E11) diabetes, mainly in the female population.
No takes yet. Share an insight, caveat, or question.
Beissova et al. (2023) conducted an observational in Diabetes Mellitus (n=1,903,243). COVID-19 pandemic period (2020-2021) vs. Pre-pandemic period (2018-2019) was evaluated on Mortality rate from diabetes (per 100,000 population). The COVID-19 pandemic was associated with a 1.5-fold increase in diabetes mortality in Kazakhstan, rising from 22.3 per 100,000 in 2018 to 34.1 per 100,000 in 2021.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: